1 suspended, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Suspended 1, Terminated 1 |
| Phase 3 | 1 | Suspended 1 |
Follow NUC-1031: new trials by email Literature Review of NUC-1031 trials Research Report on NUC-1031
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer NUC-1031 500 mg, NUC-1031 750mg - Ovarian Cancer | Phase 2 | Terminated | NuCana plc | 53 | 2017-09-28 | 2021-02-21 |
| Acelarin First Line Randomised Pancreatic Study Acelarin, Gemcitabine - Pancreatic Acinar Carcinoma, Pancreatic Neoplasms | Phase 2 / Phase 3 | Suspended | The Clatterbridge Cancer Centre NHS Foundation Trust | 328 | 2015-12-01 | 2019-10-29 |
Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Diseases (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
NuCana plc (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1)
United Kingdom (2) · United States (1)
Daniel H Palmer, BSC, PhD (1) · Elisabeth Oelmann, MD PhD (1)
2016 (1)